logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Influenza

    FiltersReset Filters
    4 results

    • oseltamivir phosphate

      (Oseltamivir phosphate)
      MSN LABORATORIES PRIVATE LIMITED
      Usage: Oseltamivir phosphate capsules are indicated for treating acute, uncomplicated influenza A and B in patients aged 2 weeks and older, symptomatic for no more than 48 hours. They are also used for the prophylaxis of influenza in individuals 1 year and older. Annual vaccination is recommended.

    • rapivab

      (peramivir)
      BioCryst Pharmaceuticals, Inc.
      Usage: RAPIVAB is indicated for treating acute uncomplicated influenza in patients aged 6 months and older when symptoms have occurred for no more than 2 days. Efficacy is mainly based on influenza A infections; limitations include potential resistance and lack of efficacy in hospitalized patients.

    • tamiflu

      (oseltamivir phosphate)
      Genentech, Inc.
      Usage: TAMIFLU is indicated for treating acute, uncomplicated influenza A and B in patients 2 weeks and older within 48 hours of symptom onset, and for prophylaxis in those 1 year and older. It is not a substitute for vaccination and has limitations regarding resistance and specific patient populations.

    • xofluza

      (BALOXAVIR MARBOXIL)
      Genentech, Inc.
      Usage: XOFLUZA is indicated for the treatment of acute uncomplicated influenza in patients aged 5 years and older within 48 hours of symptom onset, as well as for post-exposure prophylaxis of influenza in the same age group after contact with an infected individual.